{"product_id":"myriad-marketing-mix","title":"Myriad Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Myriad’s product design, pricing architecture, channel strategy and promotional mix combine to create competitive advantage. This preview highlights key tactics and market positioning across the 4Ps. Get the full, editable Marketing Mix Analysis for detailed data, examples, and presentation-ready insights to save research time and boost strategic impact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHereditary cancer risk panels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad’s hereditary cancer risk panels use comprehensive multi-gene testing to detect inherited risk for breast, ovarian, colorectal and other cancers, with BRCA1\/2 accounting for roughly 5–10% of breast cancers. Panels emphasize clinical validity, guideline-aligned actionable reports and deliver risk scores plus management insights for clinicians. Packaging includes intuitive, clinician-facing reports and integrated genetic counseling support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTumor profiling and companion diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAssays characterize tumor biomarkers to guide targeted therapies and inform prognosis, detecting actionable alterations in roughly 40–60% of advanced solid tumors. Tests are designed to meet companion diagnostic and regulatory standards. Reports highlight therapy matches and relevant clinical trials, and turnaround times are optimized for oncology workflows, typically 7–10 business days.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen’s health genetic testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWomen’s health genetic testing by Myriad offers carrier screening panels covering 200+ conditions, prenatal diagnostics, and reproductive risk tests tailored for OB\/GYN settings, supporting family planning and pregnancy management decisions. Results are delivered in clear reports with provider guides to streamline interpretation and clinical action. Patient education materials accompany testing to reduce uncertainty and increase adherence to recommended follow-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacogenomics for mental health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePharmacogenomic testing guides antidepressant and psychotropic selection, aiming to improve the ~30–50% remission rate seen with first-line therapy by reducing nonresponse and side effects. Reports stratify gene–drug interactions into actionable bins (use as directed, consider alternative, avoid) and provider tools map results to prescribing actions; panels and labels are updated regularly to reflect new evidence and FDA label changes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGuides selection\u003c\/li\u003e\n\u003cli\u003eActionable bins\u003c\/li\u003e\n\u003cli\u003ePrescriber tools\/EHR\u003c\/li\u003e\n\u003cli\u003eOngoing label updates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital tools and clinical support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSecure portals enable test ordering, tracking and results review while decision-support layers deliver guideline-aligned summaries and follow-up recommendations; Myriad pairs these with integrated tele-genetic counseling and patient support to boost adherence. Platforms are built with HIPAA and GDPR compliance and leverage the US genetic counseling workforce of over 5,000 professionals (NSGC 2024).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSecure portals: ordering, tracking, results\u003c\/li\u003e\n\u003cli\u003eDecision support: guidelines, summaries, follow-up\u003c\/li\u003e\n\u003cli\u003eIntegrated counseling: tele-genetics, patient support\u003c\/li\u003e\n\u003cli\u003eSecurity\/compliance: HIPAA, GDPR\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated genomic testing: hereditary, tumor, carrier and PGx reports for faster care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad’s product suite combines comprehensive hereditary cancer panels (BRCA1\/2 ~5–10% of breast cancers), tumor biomarker assays detecting actionable alterations in ~40–60% of advanced solid tumors, 200+ condition carrier\/prenatal panels, and pharmacogenomic reports reducing trial‑and‑error prescribing. Clinician reports, 7–10 business day oncology TAT, integrated tele‑genetics and HIPAA\/GDPR compliance support clinical uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHereditary panels\u003c\/td\u003e\n\u003ctd\u003eBRCA1\/2 5–10%\u003c\/td\u003e\n\u003ctd\u003eRisk stratification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTumor assays\u003c\/td\u003e\n\u003ctd\u003e40–60% actionable\u003c\/td\u003e\n\u003ctd\u003eTherapy selection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWomen’s health\u003c\/td\u003e\n\u003ctd\u003e200+ conditions\u003c\/td\u003e\n\u003ctd\u003eFamily planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePGx\u003c\/td\u003e\n\u003ctd\u003eImproves initial remission*\u003c\/td\u003e\n\u003ctd\u003ePrescribing guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery\u003c\/td\u003e\n\u003ctd\u003e7–10 days; 5,000 GC (NSGC 2024)\u003c\/td\u003e\n\u003ctd\u003eClinical integration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a company-specific deep dive into Myriad's Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to highlight positioning, tactical examples, and strategic implications for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eMyriad 4P's condenses complex marketing strategy into a clean, customizable one‑pager—ideal for leadership briefings, team alignment, or rapid comparison across brands—saving time and clarifying priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-clinician distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSales and service teams engage oncologists, OB\/GYNs, primary care, and psychiatrists to drive test adoption across specialty and general practice. Test kits are supplied to clinics with streamlined prepaid return logistics and centralized processing to reduce turnaround. Clinical liaisons support ordering workflows and result interpretation at point of care. Coverage prioritizes high-volume settings to maximize patient access and clinician uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and health system partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmbedded programs place testing into oncology and women’s health pathways, shortening clinical loops and aligning with multi-site systems that now include about 63% of US hospitals; co-developed workflows improve specimen handling and can cut NGS turnaround to a median of ~7 days; streamlined contracting eases roll-out across networks; secure data-sharing feeds quality initiatives and outcomes registries covering ~4,500 hospitals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital portals and EHR integrations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOnline ordering and real-time status tracking cut administrative friction for providers and patients, streamlining workflows and reducing call volume. EHR connectivity supports e-consent, automated eligibility checks and direct result delivery into charts; 96% of US hospitals use EHRs (ONC) and CMS mandated FHIR-based APIs in 2021. Embedded decision-support prompts increase guideline-concordant testing, and scalable APIs enable enterprise integrations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNationwide sample logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKits support blood, saliva, and tissue with standardized collection protocols; nationwide couriers and validated cold-chain processes maintain sample integrity, with industry-preserved integrity rates exceeding 95% in 2024. Turnaround SLAs are tiered to clinical urgency—oncology samples prioritized for 24–48 hour processing—and visibility tools provide real-time notifications to clinicians at each step.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSample types: blood, saliva, tissue\u003c\/li\u003e\n\u003cli\u003eIntegrity benchmark: \u0026gt;95% (2024)\u003c\/li\u003e\n\u003cli\u003eCoverage: nationwide courier networks\u003c\/li\u003e\n\u003cli\u003eOncology SLA: 24–48 hours\u003c\/li\u003e\n\u003cli\u003eReal-time clinician notifications: near real-time tracking\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelect international presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSelect international presence focuses on regions with supportive reimbursement and clinical guidelines, advancing expansion activity in 2024 into markets prioritizing genomic oncology. Local partners and accredited labs manage regulatory compliance and credentialing, while localized reports and multilingual support materials drive clinician adoption. Market entry emphasizes oncology centers of excellence to accelerate referrals and validation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegions: reimbursement-aligned markets (2024 focus)\u003c\/li\u003e\n\u003cli\u003eCompliance: local lab partnerships for regulatory clearance\u003c\/li\u003e\n\u003cli\u003eLocalization: translated reports + clinician support\u003c\/li\u003e\n\u003cli\u003eChannel: oncology centers of excellence prioritized\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKits \u0026gt;95% integrity, SLA 24–48h, NGS ~7d across ~4,500 hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSales\/service teams target oncologists, OB\/GYNs, PCPs and psychiatrists to drive adoption; kits (blood\/saliva\/tissue) use nationwide couriers, \u0026gt;95% integrity (2024) and oncology SLAs of 24–48h with median NGS ~7 days. EHR\/FHIR integrations (96% hospital EHR adoption; CMS FHIR mandate 2021) enable e-consent, automated eligibility and real-time results across ~4,500 hospitals\/networks (63% US hospitals).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegrity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS median TAT\u003c\/td\u003e\n\u003ctd\u003e~7 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology SLA\u003c\/td\u003e\n\u003ctd\u003e24–48h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals covered\u003c\/td\u003e\n\u003ctd\u003e~4,500 (~63% US)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEHR adoption\u003c\/td\u003e\n\u003ctd\u003e96% (ONC)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eMyriad 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Myriad 4P's Marketing Mix Analysis you’ll receive after purchase—fully complete and editable. No samples or mockups: download the identical, high-quality document instantly at checkout and use it immediately for strategy or presentations. Buy with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56164550377849,"sku":"myriad-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/myriad-marketing-mix.png?v=1762736435","url":"https:\/\/portersfiveforce.com\/products\/myriad-marketing-mix","provider":"Porter's Five Forces","version":"1.0","type":"link"}